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Manganese-52: applications in cell radiolabelling
and liposomal nanomedicine PET imaging using
oxine (8-hydroxyquinoline) as an ionophore†
Peter Gawne, a Francis Man, a Jesper Fonslet,b Riya Radia,a Jayanta Bordoloi,a
Matthew Cleveland,c Pilar Jimenez-Royo,c Alberto Gabizon,d Philip J. Blower, a
Nicholas Long e and Rafael T. M. de Rosales *a
The ionophore 8-hydroxyquinoline (oxine) has been used to radiolabel cells and liposomal medicines
with 111In and, more recently, 89Zr, for medical nuclear imaging applications. Oxine has also shown prom-
ising ionophore activity for the positron-emitting radionuclide 52Mn that should allow imaging of labelled
cells and nanomedicines for long periods of time (>14 days). However, to date, the radiometal complex
formed and its full labelling capabilities have not been fully characterised. Here, we provide supporting
evidence of the formation of [52Mn]Mn(oxinate)2 as the metastable complex responsible for its ionophore
activity. The cell labelling properties of [52Mn]Mn(oxinate)2 were investigated with various cell lines. The
liposomal nanomedicine, DOXIL® (Caelyx) was also labelled with [52Mn]Mn(oxinate)2 and imaged in vivo
using PET imaging. [52Mn]Mn(oxinate)2 was able to label various cell lines with moderate eﬃciency
(15–53%), however low cellular retention of 52Mn (21–25% after 24 h) was observed which was shown not
to be due to cell death. PET imaging of [52Mn]Mn-DOXIL at 1 h and 24 h post-injection showed the
expected pharmacokinetics and biodistribution of this stealth liposome, but at 72 h post-injection showed
a proﬁle matching that of free 52Mn, consistent with drug release. We conclude that oxine is an eﬀective
ionophore for 52Mn, but high cellular eﬄux of the isotope limits its use for prolonged cell tracking. [52Mn]
Mn(oxinate)2 is eﬀective for labelling and tracking DOXIL in vivo. The release of free radionuclide after
liposome extravasation could provide a non-invasive method to monitor drug release in vivo.
Introduction
Ionophores are organic ligands that facilitate transport of
metal ions passively across lipid bilayers. In particular, iono-
phores have been widely used since the 1970s to directly label
and image both cells and liposomal medicines in vivo with
radiometals using clinical nuclear imaging techniques such as
single-photon emission tomography (SPECT) and more
recently positron emission tomography (PET). Ionophore
ligands are usually lipophilic and have low denticity. Binding
of the radiometal with the ionophore results in a complex that
is both lipophilic and uncharged, and able to passively cross
lipid bilayers (Scheme 1). The radiometal-ionophore complexes
are commonly meta-stable and dissociate inside the cell/lipo-
Scheme 1 Diagram showing the proposed mechanism of labelling cells
and liposomes using radio-ionophore complexes. (A) The neutral lipo-
philic radio-ionophore complex crosses lipid bilayer. (B) The meta-stable
complex dissociates and (C) the radio-metal binds to intracellular pro-
teins/macromolecules or drugs with chelating groups within liposomal
medicines.
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some, at which point trapping occurs via the binding of the
radiometal to intracellular proteins1 or intraliposomal drug
molecules – provided they have chelating groups – or other
metal-chelating ligands (Scheme 1).2 As such, eﬀective radio-
ionophore agents should facilitate fast uptake and slow radio-
nuclide eﬄux, whilst not aﬀecting the viability or function of
cells/liposomes.
The longitudinal imaging/tracking of living cells and lipo-
somal nanomedicines within a living organism has appli-
cations in locating inflammation (labelled leukocytes) and
determining the biodistribution of therapeutic cells and
nanomedicines. To allow this, the choice of radionuclide is
important. One of the most widely used radio-ionophore
complexes to date is the tris(oxinate) complex of the gamma-
emitting radionuclide 111In (t1/2 = 2.8 days) (Fig. 1A). Known
as “[111In]In-oxine” this compound has been used clinically since
the 1980s to radiolabel autologous leukocytes for imaging of
infection and inflammation in vivo,3,4 and was recently with-
drawn from the EU market due to the perceived low cost-eﬀec-
tiveness by the supplier.5 More recently, it has regained atten-
tion for its ability to directly label and track a variety of
immune cells.6–11 With the growing availability of PET, focus
has shifted towards the development of PET tracers for cell lab-
elling. PET imaging oﬀers higher sensitivity than SPECT
imaging as well as improved spatial resolution and quantifi-
cation in the clinical setting.12 In particular, 89Zr complexes
(t1/2 = 3.27 days; β
+ = 22.3%) have been investigated as PET
alternatives to [111In]In-oxine. Zirconium and indium have
similar preferred ligand types – despite the diﬀerent
preferred oxidation states (In(III) and Zr(IV)) – as well as having
similar half-lives,1 and the PET tracer [89Zr]Zr(oxinate)4 (also
known as [89Zr]Zr-oxine, Fig. 1B) has shown excellent cell
labelling and tracking properties.1,13 The longer half-life of
89Zr, combined with improved cellular retention of the radio-
nuclide compared to 111In,13 allowed more prolonged in vivo
cell tracking with PET (7–14 days) with various cell types.13–15
[89Zr]Zr(oxinate)4 has also been used to directly label and track
liposomal medicines in vivo for up to 7 days, without the need
for modification of the nanomedicine or interference with its
manufacture.2
In our search for new radiometals to track cells/nanomedi-
cines with PET for longer periods of time we turned our atten-
tion towards 52Mn (t1/2 = 5.59 days, β
+ = 29.6%). Recently we
have shown that oxine has promising 52Mn ionophore activity
in vitro using liposomes as a model.2 The radiolabelling yields
and in vitro serum stability properties where comparable to
those obtained with [89Zr]Zr(oxinate)4. However, the identity of
the [52Mn]Mn-oxine complex was not known and its cell label-
ling and in vivo liposome tracking ability was unexplored. Here,
we describe the synthesis and characterisation of the radiometal
complex [52Mn]Mn(oxinate)2 (Fig. 1C) and evaluated its cell-
labelling properties. Additionally, the in vivo stability and bio-
distribution of 52Mn-labelled liposomes, radiolabelled with this
radiotracer, were investigated in mice with PET imaging using
the clinically approved nanomedicine DOXIL® (Caelyx).
Results and discussion
Radiosynthesis of [52Mn]Mn(oxinate)2
[52Mn]Mn(oxinate)2 can be synthesised rapidly and reliably by
the addition of oxine (from a DMSO stock solution) to [52Mn]
MnCl2 in dilute HCl, followed by neutralisation with 0.1 M
ammonium acetate solution (pH 7) and a brief heating step at
50 °C (Fig. 2A). Instant thin layer radiochromatography (iTLC)
analysis using a mobile phase of 25% methanol in chloroform
shows that whereas [52Mn]MnCl2 stays at the baseline (Rf = 0)
radioactivity of the product solution migrates with the solvent,
indicating the formation of the expected lipophilic compound.
Rf values for the oxine compound were inconsistent (Rf =
0.3–0.8) most likely due to varying amounts of DMSO present
in the reaction mixture. The radiochemical yield (RCY) was
69 ± 20% (n = 3) based on iTLC analysis, which we also used as
an estimate of the radiochemical purity. The lipophilicity of
[52Mn]Mn(oxinate)2 was confirmed with log P measurements
using octanol/water solvent extraction (log Pwater = 1.5 ± 0.1),
whereas the log P of 52MnCl2 showed the expected high hydro-
philicity of a hydrated manganese ion (log P = −1.2 ± 0.3)
(Fig. 2B). The synthesis of [52Mn]Mn(oxinate)2 has benefits
over [89Zr]Zr(oxinate)4: it does not require the solvent extrac-
tion step required to remove oxalate/oxalic acid from the final
[89Zr]Zr(oxinate)4 product, involving vigorous vortexing fol-
lowed by separation and evaporation of the organic layer
(CHCl3). Sato et al. recently reported an improved synthetic
method for [89Zr]Zr(oxinate)4 from [
89Zr]ZrCl4 in aqueous
media, however vortexing of the mixture was still necessary.14
Fig. 1 Structures of the radio-ionophore complexes discussed: [111In]In(oxinate)3 (A), [
89Zr]Zr(oxinate)4 (B) and [
52Mn]Mn(oxinate)2 (C).
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Synthesis and characterisation of natMn(oxinate)2
To determine the chemical identity of the species formed
during radiosynthesis we synthesised and characterised the
non-radioactive 55Mn(oxinate)2 complex (
55Mn = natMn = Mn =
naturally occurring Mn). This was achieved by addition of 0.5
equivalents of MnCl2 to a basic solution of 8-hydroxyquinoline
– deprotonated with one equivalent of potassium hydroxide –
resulting in the formation of a pale yellow precipitate.
Formation of the bis-oxinate Mn(II) complex was confirmed
with mass spectrometry (electrospray in positive mode) with a
m/z peak at 344.0348 consistent with a protonated
Mn(oxinate)2 complex (M + 1) and another peak at 687.0684 relat-
ing to a protonated 2[Mn(oxinate)2] species (2M + 1) (Fig. S1†).
No peaks were observed with m/z matching a ligand-to-metal
stoichiometric ratio of 3 : 1, suggesting that the oxidation of
the metal to form a Mn(oxinate)3 complex had not occurred.
Additionally, IR spectroscopy showed a reduction of the broad
O–H stretch band at 2700–3400 cm−1 upon metal complexa-
tion – relating to the deprotonation of the hydroxyl associated
with formation of the Mn–O bond (Fig. S2†). Further analysis
of Mn(oxinate)2 complex was limited by its insolubility in all
the organic solvents tested. Whilst previous work has reported
the synthesis of Mn(oxinate)2,
16,17 few reports have character-
ised the structure of the manganese complex. Li et al. reported
the 1D coordination polymer of [Mn(oxinate)2]n and showed
each Mn2+ ion was bound to the oxine ligand in a severely dis-
torted N2O4 octahedral geometry.
18 However the high tempera-
ture (453 K) synthesis method used in this case limits compar-
ability with the compound synthesised herein.
To gain further insight into the preferential stoichiometry
of the complex being formed in the radiochemical reaction,
UV-vis spectrophotometric titrations were carried out (repre-
sentative spectra in Fig. S3†). Unlike other characterisation
spectroscopic methods such as NMR, the low concentrations
of reactants required for UV-vis spectrometry are comparable
to those in radiochemistry which is always performed at low
radiometal concentrations and metal-to-ligand ratios. Thus,
the change in the absorbance spectrum of a 0.1 mM 8-hydroxy-
quinoline solution (1.46% v/v DMSO in 1 mM ammonium
acetate solution) was monitored upon titration of increasing
equivalents of MnCl2 at pH 7–9 (Fig. 3A–C and S3†). Upon
addition of MnCl2, an increase in an absorption band with
λmax = 255 nm was observed across each pH. In the absence of
oxine, no increase in absorbance was seen, demonstrating that
the absorbance increase is due to metal–ligand binding. At
each pH, a decrease in the absorbance change occurred after
0.5 equivalents of MnCl2, indicating the preferential formation
of the bis-oxine complex. This was particularly prominent with
increasing pH values (e.g. pH 9) which is consistent with the
relatively high pKa of the hydroxyl group from the oxine ligand
(pKa = 11.54).
19 Additionally, the absorbance at 255 nm was
plotted as a function of the mole fraction (relative proportion,
or fraction, of a compound in solution) of MnCl2 added
(known as a Job plot20). The Job plot in Fig. 3D showed that
the change in absorption decreased once a mole fraction of
MnCl2 reached 0.33, characteristic of a ML2 complex (where
M = Mn; L = 8-hydroxyquinoline). In the case of Mn(oxinate)3
(ML3) being preferentially formed, the absorption would be
seen to decrease at a mole fraction of 0.25 – which we did not
observe. Additionally, electron paramagnetic resonance (EPR)
spectroscopy of a solution of 1 mM oxine (1.46% v/v DMSO in
1 mM ammonium acetate solution) mixed with 0.5 equivalents
of MnCl2 showed the presence of Mn
2+ (Fig. S4†). These
results lead us to propose that the chemical species formed
during the radiosynthesis is [52Mn]Mn(oxinate)2.
Another important aspect of the direct cell radiolabelling
strategy is that the compound (i.e. Mn(oxinate)2) must be meta-
stable, with suﬃcient stability to cross the cell membrane but
unstable enough to decompose inside the cell releasing the
radiometal (Scheme 1). To test the metastability of
Mn(oxinate)2, we monitored its absorbance at 255 nm using
the same conditions as in the UV-vis titrations. We observed
gradual decomposition of the complex indicated by a decrease
in the absorption (Fig. S5†). This process, however, is slow and
only a small fraction of decomposition is evident after 1 h.
Taking into account that direct cell labelling using ionophores
is fast (<30 min), and that metastability is required for metal
release inside the cells, these results further support the use of
this complex for direct cell labelling.
In vitro cell labelling with [52Mn]Mn(oxinate)2
The cell labelling properties of [52Mn]Mn(oxinate)2 were
assessed in three diﬀerent cell lines and in human platelets.
Table 1 summarises the cell labelling eﬃciencies and cellular
Fig. 2 (A) Radiochemical scheme for the synthesis of [52Mn]Mn(oxinate)2, and (B) chart showing the log P values of unchelated
52Mn and [52Mn]
Mn(oxinate)2 in water/octanol. Error bars represent standard deviation (n = 2).
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retention of 52Mn. Across all cell types, the presence of oxine
resulted in higher cellular uptake compared to that achieved
with the unchelated 52Mn control, demonstrating the iono-
phore properties of oxine for Mn(II). The presence of excess
amounts of a similar divalent metal such as Ca2+ in the cell
medium (1.8 mM) during the MDA-MD-231 radiolabeling
experiments, compared to the pM-nM concentrations of
[52Mn]Mn(oxinate)2, demonstrates suﬃcient complex inertness
for direct cell labelling. This was surprising due to the simi-
larity of these two metals and the expected lability of the
Mn(oxinate)2 complex. Furthermore, UV-vis studies demonstrated
oxine selectivity for Mn2+ by showing complete formation of
natMn(oxinate)2 even in the presence of a large excess (up to 20
eq.) of Ca2+ (Fig. S6†). The cell labelling ability of [52Mn]Mn
(oxinate)2 was directly compared to that of [
89Zr]Zr(oxinate)4 in
gamma-delta T-cells. Interestingly, [52Mn]Mn(oxinate)2 showed
comparable cell labelling eﬃciency to [89Zr]Zr(oxinate)4 (45.6 ±
29.1% and 46.6 ± 6.8%, respectively), suggesting that the
number of oxine ligands in the primary coordination sphere of
these metal complexes is not an important factor. Retention of
52Mn in these cells after 24 h, however, was approximately
three times lower than that of 89Zr (27.1 ± 6.8% and 74.9 ±
6.2%, respectively) (Fig. 4A). Further analysis with 52Mn-
labelled MDA-MB-231 breast cancer cells showed that cellular
eﬄux of 52Mn from labelled cells occurs rapidly with over 50%
of the initial intracellular 52Mn leaving the cells after 4 hours.
This result confirms this eﬄux is fast and not cell-specific, at
least for the cells tested in this work (Fig. 4B). A possible expla-
nation for this rapid eﬄux of the radiometal is cell death due
to the radiolabelling process. However, a cell viability assay
comparison (trypan blue) showed no diﬀerent between
MDA-MB-231 cells labelled with [52Mn]Mn(oxinate)2 (0.05 Bq
per cell) and non-labelled cells, both immediately and 24 h
after labelling (Fig. 4C). To investigate the cellular eﬄux of
52Mn further, aliquots of the cell supernatant were taken at
various time points during the 30 min labelling period of
MDA-MB-231 cells and lipophilicity measurements of this
solution were performed to identify the nature of the radio-
active species. At each time point log P values of the 52Mn
species in the supernatant were negative/hydrophilic (ca. −1.5)
Fig. 3 UV-vis titration (λ = 255 nm) of MnCl2 into a 0.1 mM solution of oxine (1.46% v/v DMSO in 1 mM ammonium acetate solution) performed at
room temperature at (A) pH 7; (B) pH 8; (C) pH 9; (D) a Job plot of mole fraction (fraction of reagent in solution) of MnCl2 versus absorbance. Mole
fraction of Mn = [χMn/(χMn + χoxine)] where χMn = total moles of MnCl2 in solution and χoxine = total moles of oxine in solution.
Table 1 Cell labelling eﬃciency of [52Mn]Mn(oxinate)2 and unchelated
52Mn. Labelling conditions: § – 106 cells incubated for 30 min at 37 °C in
3 mL cell medium; † – 5×106 cells per mL incubated for 20 min at room temperature; ‡ – 108 cells per mL incubated for 30 min at 37 °C. All values
given as mean ± standard deviation. * – single experiment carried out in triplicate
Cell line labelled (LE = labelling eﬃciency) [52Mn]Mn(oxinate)2 LE (%) Unchelated
52Mn LE (%)
Breast cancer cells§ (MDA-MB 231) 33.4 ± 9.2 (n = 5) 3.9 ± 3.2 (n = 5)
Human embryonic kidney cells (HEK-293T)§ 52.8 ± 3.8* 8.5 ± 0.6*
Gamma delta (γδ) T-cells† 45.6 ± 29.1 (n = 3) 0.9 ± 0.4 (n = 3)
Human blood platelets‡ 14.8 ± 1.1* 2.7 ± 0.1*
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whereas the log P value for [52Mn]Mn(oxinate)2 in cell-free
medium was positive/lipophilic (0.88) (Fig. 5). These results
indicate that: (i) 52Mn, after entering the cell as part of a lipo-
philic compound, leaves the cell in a hydrophilic form, and (ii)
the hydrophilic log P values obtained during incubation
cannot be fully explained by decomposition of [52Mn]
Mn(oxinate)2 in cell medium.
These results together suggest that 52Mn leaves the cell via
a specific cellular pathway. Manganese is a biologically essen-
tial metal found in a variety of tissues. It is particularly impor-
tant for the catalytic activity of the mitochondrial enzyme
superoxide dismutase (Mn-SOD) to detoxify reactive oxygen
species.21,22 Mn is neurotoxic, and Mn2+ can cross the BBB
barrier via the divalent metal transporter-1 (DMT-1).23–25
Hence, human biology has evolved mechanisms to manage
and transport manganese ions eﬃciently, and calcium chan-
nels are known to be permeable to Mn2+. However, little is
known about the intracellular handling of this element.24
Similar rapid cellular eﬄux was previously reported when lab-
elling cells with 64Cu, using the lipophilic, redox-active
complex Cu(PTSM) (PTSM = pyruvaldehyde-bis(N4-methyl-
thiosemicarbazonate)) which is known to release copper bio-
reductively immediately on entry into cells.26,27 In these studies,
after using this compound to label C6 glioma cells and murine
Th1 cells, just 38% and 47%, respectively, of the radiolabel
was retained 5 h post-labelling.26,27 Copper, like manganese,
has several biological roles and the low retention of 64Cu may
also be due to an active cellular process. If radiomanganese
leaves the cell due to a cellular process, this may limit the tech-
nique of directly labelling cells using 52Mn ionophores.
Fig. 4 (A) Graph comparing the labelling eﬃciency (left) and cellular retention after 24 h (right) of [52Mn]Mn(oxinate)2 (green) with that of [
89Zr]
Zr(oxinate)4 (blue) in gamma-delta (γδ) T-cells. (B) Cellular retention of 52Mn over 24 h in MDA-MB 231 cells. (C) Cell viability of MDA-MB 231 cells
radiolabelled with [52Mn]Mn(oxinate)2 (50 KBq per 10
6 cells) compared to unlabelled controls. All error bars represent standard deviation (n = 3).
Fig. 5 Log P analysis of cell supernatant of MDA-MB 231 cells labelled
with [52Mn]Mn(oxinate)2. Log P values of supernatant taken during the
30 min labelling period show a negative (hydrophilic value) compared
with the lipophilicity value of [52Mn]Mn(oxinate)2 in cell-free medium
(green bar on left). Error bars represent standard deviation (n = 3) except
for the log P of [52Mn]Mn(oxinate)2 which is a single experiment per-
formed in triplicate.
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Although the tracer may be used to track cells at earlier time
points, the rate of eﬄux means that the long half-life of the
isotope – and the resulting radiation dose – cannot alone
justify use of 52Mn for this application.
Liposome (DOXIL/CAELYX) labelling with [52Mn]Mn(oxinate)2
for in vivo PET imaging
In addition of being used to label cells directly, our group has
recently shown that oxine is an excellent ionophore for radio-
metal labelling of liposomal nanomedicines that encapsulate
metal-chelating drugs, including preliminary in vitro work with
52Mn.2 Interestingly, [52Mn]Mn(oxinate)2 eﬃciently radio-
labelled the FDA-approved nanomedicine DOXIL/CAELYX®
(PEGylated liposomal doxorubicin) with high eﬃciency (>80%)
and high in vitro human serum stabilities (ca. 95% after 72 h
at 37 °C).2 The high retention of 52Mn inside the doxorubicin-
loaded liposome is not surprising as Mn2+ has previously been
shown to drive the loading of doxorubicin into liposomes by
forming an stable intraliposomal Mn-doxorubicin complex.28
Abraham et al. characterised the complexation between Mn2+
and doxorubicin showing that the metal coordinates with a
bidentate site consisting of the carbonyl and hydroxyl groups
on the central aromatic ring system.29
The longitudinal imaging of liposomal medicines in vivo
not only gives information on their biodistribution, but can be
used to predict the eﬃcacy of new treatments.30,31 In particu-
lar, imaging can provide information supporting ‘personalised
medicine’ in which the response to liposomal therapies can be
predicted from patient-to-patient. For this, particular focus has
been placed on the use of nuclear imaging techniques because
their high sensitivity gives them the ability to image thera-
peutic nanomedicines using very low doses which have a
reduced or no physiological eﬀect (microdosing).32 The radi-
olabelling technique developed by our group diﬀers from pre-
vious methods developed in which the radiometal is chelated
to ligands on a modified lipid bilayer,30,33,34 as well as direct
incorporation of the radio-isotope into the lipid molecule
itself.35 The use of radio-ionophore complexes for directly lab-
elling liposomes with PET radionuclides has been previously
reported by others with 64Cu (t1/2 = 12 h; β
+ = 17.8%) and
recently 52Mn – using a variety of ionophores, including oxine.
However, in each case a drying step, involving high tempera-
tures and a stream of argon is necessary to remove solvents
before incubation with the liposomes.36,37 Additionally, the
radiometal was trapped internally by an encapsulated DOTA
chelator; hence modification of the liposomal medicine is
necessary. By taking advantage of the chelating properties of
some drugs, already-formulated liposomal nanomedicines can
easily be labelled and tracked in vivo without the need for
external modification of the nanomedicine or interfering with
its manufacture – which may potentially aﬀect the biodistribu-
tion of the nanodrug.
Following on from our previous in vitro work describing
the radiolabeling of DOXIL/CAELYX® ([52Mn]Mn-DOXIL)
with 52Mn using oxine, here we describe the evaluation of
the method to image the in vivo biodistribution and stability
of [52Mn]Mn-DOXIL in mice using PET. Whilst previous
work has described the labelling and imaging of DOXIL with
technetium-99m,38 rhenium-186,39 and indium-111,40 this
is the first time to the best of our knowledge that it has been
tracked using PET imaging. [52Mn]Mn-DOXIL was prepared
with a labelling eﬃciency of >80%. At 1 h post-injection
(p.i.) of [52Mn]Mn-DOXIL (1 MBq, 5 mg kg−1 doxorubicin
dose) in female B6CBAF1 mice, the majority of the radio-
activity was observed in the bloodstream, with high signal in
the heart and major blood vessels such as the carotid
arteries and descending aorta (Fig. 6A). Some activity in
these regions remained at 24 h p.i., with increasing uptake
in the liver and spleen. This slow transition from the blood-
stream at early time points to the gradual accumulation in
the spleen and liver is typical of “stealth” PEGylated lipo-
somal nanomedicines such as DOXIL; the stealth properties
of these liposomes inhibit recognition by the mononuclear
phagocyte system/reticuloendothelial system (MPS/RES).41,42
The circulation half-life of [52Mn]Mn-DOXIL was calculated
by measuring radioactivity in blood samples taken at
specific time points (Fig. 6B). The data were fitted to a one-
compartment pharmacokinetic model that allowed the cal-
culation of the circulation half-life (t1/2) and area under the
curve (AUC). Thus, the calculated circulation half-life (t1/2)
was 33.6 h, typical of a stealth nanomedicine and similar to
that calculated by other preclinical studies with DOXIL/
CAELYX (20–30 h).38,39,42 This also confirms that radiolabel-
ling is stable while in the bloodstream (since the observed
biodistribution does not match that of free 52Mn, see
below).
Despite the confirmed stability of [52Mn]Mn-DOXIL in cir-
culation and observation of the expected biodistribution at
early time points, the PET images at 72 h p.i. (Fig. 6A)
showed a profile characteristic of unchelated 52Mn (high
signal in kidneys, pancreas and salivary glands43,44). This was
confirmed by ex vivo biodistribution studies at 72 h p.i.
(Fig. 6C) that demonstrated high radioactivity in these organs
(kidneys (20 ± 3%ID g−1), pancreas (11 ± 2%ID g−1) and sali-
vary glands (8 ± 2%ID g−1)). Conversely, spleen and liver
uptake, commonly the organs with higher liposome presence
at this timepoint, were relatively low (9 ± 3%ID g−1 and 11 ±
2%ID g−1, respectively) compared to other studies with
stealth liposomes of similar physicochemical characteristics.2
Image-based quantification of the PET images is in agree-
ment with these findings (Fig. S7†). Release of the contents
of the liposomal nanodrug over time is expected, and indeed
is required for anti-tumour eﬃcacy, and has been previously
observed. For example, previous work from our group noted
increasing activity uptake in the bone over time when track-
ing 89Zr-labelled liposomal nanodrugs – indicative of the free
radionuclide that is supposedly released when the liposomes
extravasate and release their contents.2 Additionally,
previous studies tracking DOXIL using [99mTc]Tc- and
[186Re]Re-BMEDA (N,N-bis(2-mercaptoethyl)-N′,N′-diethyl-
ethylenediamine) complexes reported increased kidney
uptake after 40 h relating to release of the radioisotope from
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metabolised liposomes.38,39 However, eﬄux of the radio-
nuclide from [52Mn]Mn-DOXIL occurs more rapidly and to a
larger extent, with signs of radionuclide eﬄux at 24 h (high
uptake in kidneys, Fig. 6A). We hypothesise this may be due
to low cellular retention of the isotope within cells compared
with 89Zr and the above-mentioned SPECT radionuclides, as
our cell labelling results with [52Mn]Mn(oxinate)2 suggest
(vide supra). Thus, after the accumulation and subsequent
destruction of [52Mn]Mn-DOXIL within the liver, the isotope –
along with the drug cargo – will be released. Consequently,
52Mn will return to the blood stream resulting in the free
52Mn biodistribution profile observed. Alternatively a similar
process may occur after [52Mn]Mn-DOXIL is taken up by
tissue/circulating macrophages. This may explain the lower-
than-expected RES uptake observed at 72 h, compared to
when tracking liposomes with 89Zr.2 Hence we propose that
[52Mn]Mn(oxinate)2 may find applications in imaging liposo-
mal biodistribution, and that the rapid eﬄux of released
52Mn from cells, and hence from tissues, makes the distri-
bution to kidneys, pancreas and salivary glands a useful bio-
marker for the subsequent release of the drug cargo from
liposomes in vivo.
Conclusions
The simplicity, eﬃciency and eﬀectiveness of 8-hydroxyquino-
line (oxine) as an ionophore for the PET isotope 52Mn for cell/
liposome radiolabelling has been demonstrated. We have pro-
vided supporting evidence that the most likely radiometal
complex species that enter cells/liposomes is [52Mn]
Mn(oxinate)2. In the context of cell labelling, [
52Mn]Mn(oxinate)2
labels cells with comparable eﬃciency to [89Zr]Zr(oxinate)4,
and does not cause cell death for up to 24 h at the activity
levels used, but the technique is limited by rapid cellular eﬄux
of 52Mn. Since manganese is an endogenous essential metal,
the rapid eﬄux is likely to be due to a native cellular eﬄux
pathway. As such, we suggest that direct cell labelling with
[52Mn]Mn(oxinate)2 may be inappropriate for long-term in vivo
cell tracking that fully exploits the long half-life of 52Mn.
DOXIL labelling with [52Mn]Mn(oxinate)2 is highly eﬃcient
and DOXIL radiolabelled in this way has high radiochemical
stability in vivo whilst in the bloodstream. After 24–72 h post
injection, as the liposomes extravasate and enter tissues/cells,
eﬄux of the radionuclide is evident from the characteristic
high uptake of manganese in kidneys, pancreas and salivary
Fig. 6 In vivo PET-CT imaging with [52Mn]Mn-DOXIL. (A) Maximum intensity projections and transverse slices through selected organs of PET/CT
images of a B6CBAF1 mouse injected with [52Mn]Mn-DOXIL (1 MBq, 5 mg kg−1 doxorubicin dosage) at 1 h post-injection (p.i.), 24 h p.i. and 72 h p.i.
CA = carotid arteries; H = heart; DA = descending aorta; L = liver; K = kidneys; S = spleen; SG = salivary glands; P = pancreas. (B) Blood pharmaco-
kinetics of [52Mn]Mn-DOXIL in B6CBAF1 mice over 72 h and blood half-life of the liposomal nanomedicine. Error bars represent standard deviation
(n = 3). (C) Radioactivity distribution of [52Mn]Mn-DOXIL at 72 h p.i. in B6CBAF1 mice. %ID g−1 were calculated from ex vivo gamma counting. Error
bars represent standard deviation (n = 3).
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glands, most likely reflecting lysis of liposomes and release of
drug. Since these organs are not usually involved in liposomal
nanomedicine clearance, the characteristic biodistribution of
free 52Mn could be used as a marker of drug release from lipo-
somes radiolabelled using this method. [52Mn]Mn(oxinate)2
may find other applications in the future as a method to incor-
porate tracer amounts of this essential metal inside cells to
study its biological traﬃcking mechanisms in vitro and in vivo.
Materials and methods
All chemical reagents were purchased from commercial
sources. Water (18.2 MΩ cm) was obtained from an ELGA
Purelab Option-Qsystem. Mass spectrometry (ES-TOF) analysis
was conducted by Lisa Haigh of the Mass Spectrometry
Service, Imperial College London. IR analysis was carried out
using a PerkinElmer Spectrum 100 FT-IR spectrometer. UV
titrations were carried out using a PerkinElmer Lambda 25
spectrometer, with samples in Brand 70 μL micro cuvettes.
Electron paramagnetic resonance (EPR) spectroscopy was per-
formed by Enrico Salvadori of the EPR Service, Queen Mary
University London. DOXIL (Caelyx) was kindly provided by the
Chemotherapy Department at Guys & St Thomas’ Hospital,
London (UK). [52Mn]MnCl2 was produced by Jesper Fonslet
from the Hevesy Lab, at the Technical University of Denmark.
Radioactivity in samples were measured using CRC-25R dose
calibrator (Capintec). iTLC-SG and SA strips were purchased
from Agilent, UK and scanned using the PerkinElmer Cyclone
Plus Storage Phosphor Imager. Gamma counting was per-
formed using a Wallac 1282 CompuGamma γ counter. The
human biological samples were sourced ethically and their
research use was in accord with the terms of the informed con-
sents under an Institutional Review Board/Ethics Committee
(IRB/EC) approved protocol. All animal studies were ethically
reviewed and carried out in accordance with the Animals
(Scientific Procedures) Act 1986 and the GSK Policy on the
Care, Welfare and Treatment of Animals.
Synthesis of Mn(oxinate)2
An aliquot of 1 M KOH solution (690 μL, 0.69 mmol, 1 eq.) was
added dropwise to a stirring mixture of 8-hydroxyquinoline
(0.1 g, 0.69 mmol, 1 eq.) in ethanol (10 mL) (1 eq.) at 55 °C.
The resulting solution was stirred at 55 °C for 0.5 h and then
at room temperature (RT) for 2 h. Manganese(II) chloride tetra-
hydrate (68 mg, 0.34 mmol, 0.5 eq.) in ethanol was then added
dropwise and the mixture stirred for 2 h at RT. The resulting
precipitate was then filtered and washed with ethanol and
water, then dried in vacuo to leave a pale yellow solid (26 mg,
22%).
IR νmax (cm
−1): 3045 w (νCH), 1605 m (νCvN), 1572 vs (νCvC),
1495 vs, 1461 vs, 1424 m, 1386 vs, 1375 vs, 1319 vs (νC–C), 1279
(νC–N) s, 1238 m, 1207 w, 1178 w, 1137 w, 1105 vs, 1059 m
(νC–O), 1034 m, 983 w, 960 w, 903 m, 870 m, 824 vs, 806 s, 787
vs, 746 vs, 739 vs, 652 m, 699 m, 583 m, 724 m.
HRMS (ES, +ve): calculated m/z for [M + H]+ 344.0352;
found: 344.0348. Calculated m/z for (2[M] + H)+ = 687.0631;
found: 687.0684. Calculated m/z for [M + H + C2H3N]
+ =
385.0618; found: 385.0805*. Calculated m/z for [M + H +
C4H8O2]
+ = 432.0876; found: 432.1399*. * = m/z with mass
error >10 ppm.
Elemental analysis: Calc. for C18H12MnN2O2: C, 53.82%;
H, 3.01%; N, 6.97% Found: C, 53.68%; H, 3.88%; N, 6.99%.
UV-titration of MnCl2 and 8-hydroxyquinoline
Within an ultra-micro cuvette a 0.1 mM solution of 8-hydroxy-
quinoline (1 mL, 1.46% v/v DMSO in 1 mM ammonium
acetate solution pH 7–9) was prepared. The molar equivalents
(0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1, 2 and 3 eq.) of an aqueous
manganese(II) chloride tetrahydrate solution were then added
sequentially, and the solution mixed with a 1000 μL pipette tip
and left to stand for 2 min. Absorbance measurements were
taken of the 0.1 mM oxine solution and after each addition of
the manganese(II) chloride solution. For the control titrations,
manganese(II) chloride were added to a solution containing no
8-hydroxyquinoline.
EPR spectroscopy
A 1 mM solution of 8-hydroxyquinoline (1 mL, 1.46% v/v
DMSO in 1 mM ammonium acetate solution pH 9) was pre-
pared. 0.5 equivalents of an aqueous solution of manganese(II)
chloride tetrahydrate solution was added. EPR measurements
of the resulting solution were performed at 100 K using an
X/Q-band Bruker Elexsys E580 spectrometer (Bruker, Germany)
equipped with a closed-cycle cryostat (Cryogenic Ltd, UK) con-
trolled by a LakeShore temperature controller. Measurements
were carried out in an X-band split-ring resonator module with
2 mm sample access (ER 4118X-MS2). Samples were loaded on
Suprasil EPR tubes (Wilmad LabGlass) with OD = 1.6 mm, ID =
1.1 mm. Baseline spectra of samples containing only the
buﬀer were also collected and used as a reference. All the
spectra presented have been baseline-subtracted.
[52Mn]MnCl2 production
52Mn was prepared according to the procedure described by
Fonslet et al.45 In brief, the manganese was produced by
16 MeV proton irradiation of natural chromium. Separation of
the 52Mn from the chromium target material was performed
by four sequential anion exchange purifications, trapping the
52Mn out of ethanol–HCl mixtures.
[52Mn]Mn(oxinate)2 radiosynthesis
An aliquot of [52Mn]MnCl2 was made up to 50 μL using chelex-
treated water. 8-Hydroxyquinoline was dissolved in DMSO
(12.5 mg mL−1) and an aliquot of this solution (4.8 μL) was
added to the [52Mn]MnCl2 solution. The mixture was neutral-
ised via addition of 0.1 M ammonium acetate (pH 7) and the
mixture was then heated at 50 °C for 15 min. iTLC-SA con-
ditions: Rf = 0.3–0.8, mobile phase = 20% MeOH in CHCl3.
RCY % = 69 ± 20%.
Paper Dalton Transactions
9290 | Dalton Trans., 2018, 47, 9283–9293 This journal is © The Royal Society of Chemistry 2018
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 2
4 
M
ay
 2
01
8.
 D
ow
nl
oa
de
d 
on
 9
/1
7/
20
19
 1
1:
45
:0
8 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
For the preparation of the unchelated [52Mn]MnCl2 solu-
tion, the above procedure was carried out, however DMSO
(4.8 μL) was added instead of the 8-hydroxyquinoline solution.
iTLC-SA conditions: Rf = 0, mobile phase = 20% MeOH in
CHCl3.
MDA-MB 231/HEK-293T cell labelling with [52Mn]Mn(oxinate)2
Tissue culture 6-well plates were seeded with 8 × 105 cells and
left for 24 h in Dulbecco’s Modified Eagle Medium (DMEM)
with 10% fetal bovine serum (FBS). The medium was removed
and replaced with 3 mL of serum-depleted medium (0% FBS).
50 kBq of [52Mn]Mn(oxinate)2 in serum-depleted medium (0%
FBS) were added to the cells (0.05 Bq per cell) which were then
incubated at 37 °C for 30 min. Subsequently, the cell medium
was removed and the cells washed with PBS (2 mL) and trypsin
(250 μL) was added and the cells incubated for 2 min to allow
trypsinisation. Cell medium (750 μL) was then added and the
cells re-suspended. The counts for the resuspended cells and
the cell supernatant plus PBS washes were measured and the
labelling eﬃciency calculated.
Cellular retention. The labelled cells were re-plated on a
6-well plate and cell medium (2 mL) was added. After incu-
bation at 37 °C for 4 or 24 h, the cell medium was removed
and the cells washed with PBS (2 mL) and trypsin (250 μL) was
added and the cells incubated for 2 min to allow trypsinisa-
tion. Cell medium (750 μL) was then added and the cells re-
suspended. The counts for the resuspended cells and the cell
supernatant plus PBS washes were measured in a gamma-
counter.
Human blood platelet labelling with [52Mn]Mn(oxinate)2
A Sepharose 4B column was washed with ∼100 mL of HEPES
Tyrode’s buﬀer. 15 mL of donor blood were centrifuged at
120g for 10 min at 25 °C. The plasma layer (cloudy yellow top
layer) was then removed and added to the column and eluted
with HEPES Tyrode’s buﬀer. The eluate was collected when it
appeared cloudy (indicating the presence of platelets) and was
subsequently centrifuged at 400g for 10 min and resuspended
in PBS (6 mL). 500 μL aliquots were taken and labelled with
100 μL of the [52Mn]Mn(oxinate)2 and free 52Mn suspensions
(in 1 mL serum-depleted medium) both in triplicate. The sus-
pensions were incubated for 30 min at 37 °C, after which the
suspensions were centrifuged at 120g for 10 min at 25 °C and
the supernatant removed. The cell pellet and supernatant were
then gamma counted.
Gamma-delta T-cell labelling with [52Mn]Mn(oxinate)2
[52Mn]Mn(oxinate)2 and/or unchelated
52Mn (300 kBq) were
added to 5 × 106 γδ T-cells (0.06 Bq per cell) in suspension in
sterile PBS (1 mL). The cells were incubated at room tempera-
ture with gentle mixing for 20 min. The cell suspensions were
then centrifuged at 700g for 5 min. The supernatant was then
removed and the cells were resuspended in PBS (500 μL) and
centrifuged again at 700g for 5 min. The supernatants were
combined and the cells resuspended in RPMI cell medium
(1 mL). Aliquots (100 μL) of the cell suspension and the super-
natant were then taken and gamma counted, and the labelling
eﬃciency calculated.
Cellular retention. 2.5 × 106 of the labelled cells were then
added to a 6-well cell culture plate and RPMI medium (3.5 mL)
was then added. The cells were then incubated for 24 h at
37 °C. The cell suspensions were then centrifuged at 700g for
5 min. The supernatant was then removed and the cells were
resuspended in PBS (500 μL) and centrifuged again at 700g for
5 min. The supernatants were combined and the cells re-sus-
pended in RPMI cell medium (1 mL). Aliquots (100 μL) of the
cell suspension and the supernatant were then taken and
gamma counted, and the retention calculated.
Cell supernatant log P measurements
0.5 MBq of [52Mn]Mn(oxinate)2 in serum-depleted medium
(0% FBS) were added to 106 cells on tissue culture plates in
serum-depleted DMEM (3 mL) which were then incubated at
37 °C for 30 min. At each time point, 5 μL of the cell medium
was removed and added to water/octanol (1 mL 1 : 1) and the
mixture vortexed for 2 min, then centrifuged for 20 s. An
aliquot (200 μL) from each layer was then removed to be
gamma counted.
Cell viability
After the labelling of the MDA-MB-231 cells with [52Mn]Mn
(oxinate)2, the cell medium was removed and the cells washed
with PBS (2 mL). The cell medium and PBS washes were com-
bined in a 15 mL falcon and trypsin (250 μL) was added and
the cells incubated for 2 min to allow trypsinisation. Cell
medium (750 μL) was then added and the cells re-suspended
and combined with cell medium and PBS washes, then centri-
fuged at 200g for 5 min. The supernatant was removed and the
cell pellet resuspended in cell medium (1 mL). An aliquot
(10 μL) was taken and mixed with trypan blue solution (10 μL).
The number of dead and alive cells were then counted on a
haemocytometer and the % cell viability calculated from the
proportion of the two.
DOXIL® labelling with [52Mn]Mn(oxinate)2
[52Mn]Mn(oxinate)2 (150 μL, 3.2% v/v DMSO in water) was
added to a solution of DOXIL (350 μL, 2 mg mL−1) and the
mixture heated with frequent agitation at 50 °C for 30 min.
The mixture was then loaded onto a PD minitrap G-25 size
exclusion column (GE Healthcare) following the manufac-
turers’ gravity protocol. The labelled liposomes ([52Mn]Mn-
DOXIL) were then obtained by adding saline (750 μL) to the
column and collecting the eluate.
PET/CT imaging
Animal imaging studies were carried out in accordance with
British Home Oﬃce regulations governing animal experimen-
tation. Female B6CBAF1 mice (9 weeks old) were anesthetised
with isofluorane (1.5–2%) during all imaging sessions.
[52Mn]Mn-DOXIL (1 MBq, 150 μL, 5 mg kg−1 doxorubicin
dosage) was injected i.v. into the mice (n = 3) at t = 0 h. PET/
CT imaging was performed at t = 1 h, 24 h and 72 h (n = 1).
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PET/CT imaging was performed for 60 min on a nanoScan
in vivo PET/CT preclinical imager (Mediso Medical Imaging
Systems, Budapest, Hungary). All PET/CT data sets were recon-
structed using a Monte Carlo based full 3D iterative algorithm
(Tera-Tomo, Mediso Medical Imaging Systems, Budapest,
Hungary). Decay correction to time of injection was applied.
CT images were obtained with 55 kVp tube voltage, 1200 ms
exposure time in 360 projections. All the images were analysed
using VivoQuant software (inviCRO, USA).
Ex vivo biodistribution
Biodistribution studies were carried out in accordance with
British Home Oﬃce regulations governing animal experimen-
tation. Three B6CBAF1 mice were culled by cervical dis-
location whilst under anaesthesia, and the organs of interest
were dissected, weighted and gamma-counted together with
standard samples of the injected radiotracer to obtain percen-
tages of the injected dose per mass values (%ID g−1) for each
organ/tissue. Additionally, at t = 1, 24 and 72 h blood
samples were taken. Whilst under anaesthetic, the tail vein of
the mouse was pricked and blood taken up in a heparinised
capillary tube (20 μL). Each sample was weighed and counted
with a γ counter (LKB compugamma), together with stan-
dards prepared from a sample of the injected [52Mn]Mn-
DOXIL.
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